Registry for 24-Hydroxylase Deficiency and CYP24A1 Mutation

This is an observational study creating a registry for people with suspected or confirmed 24-hydroxylase deficiency, a condition that affects how your body processes vitamin D. The registry aims to gather information about patients with this condition to help doctors and researchers better understand and treat it. You might be able to join if you or a family member has had genetic testing for a CYP24A1 mutation and also have at least three of the following: kidney stones (urinary stone disease), calcium deposits in the kidneys (nephrocalcinosis), bone problems (metabolic bone disease), high calcium levels in your blood, low parathyroid hormone (PTH) levels, or high 1,25-dihydroxyvitamin D levels. The main goal of this study is to establish and maintain this registry, which will be measured yearly. The current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will collect information without providing any specific interventions. The study plans to include 600 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint of establishing and maintaining the registry is measured yearly.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03478761

24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry

Recruiting
Not specifiedAll AgesObservational
Mayo Clinic
~600 participants
Updated 2026-03-20 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
establish and maintain a registry of suspected and confirmed patients with 24 hydroxylase deficiency
Measured over yearly
24-hydroxylase Deficiency

NCT03478761

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • David Sas, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic
  • Peter Tebben, MD · STUDY_DIRECTOR · Mayo Clinic

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Urinary Stone Disease
Nephrocalcinosis
Metabolic Bone Disease
Serum Calcium \>/= 9.6 mg/dL
Parathyroid hormone (PTH) \< 30 pg/mL
1,25-dihydroxyvitamin D \> 40 pg/mL OR a family member of a patient who meets the above criteria

Exclusion

Sarcoidosis
Lymphoma
Tuberculosis
Fungal infections
Excessive exogenous calcium or vitamin D intake
  • establish and maintain a registry of suspected and confirmed patients with 24 hydroxylase deficiencyyearly

    This patient registry will expand knowledge of the clinical expression of this disease by systematically accumulating and analyzing information regarding a larger number of patients than have been studied to date.